Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Supernus Pharmaceuticals (NASDAQ:SUPN) reported its Q3 earnings results on Wednesday, November 8, 2023 at 04:05 PM.
Here's what investors need to know about the announcement.
Supernus Pharmaceuticals missed estimated earnings by 323.08%, reporting an EPS of $-0.29 versus an estimate of $0.13.
Revenue was down $23.47 million from the same period last year.
Last quarter the company beat on EPS by $0.21 which was followed by a 7.23% drop in the share price the next day.
Here's a look at Supernus Pharmaceuticals's past performance:
Quarter | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
---|---|---|---|---|
EPS Estimate | -0.23 | 0.17 | 0.68 | 0.36 |
EPS Actual | -0.02 | 0.29 | 0.43 | 0.03 |
Revenue Estimate | 144.38M | 139.02M | 180.37M | 172.48M |
Revenue Actual | 135.56M | 153.76M | 167.33M | 177.35M |
To track all earnings releases for Supernus Pharmaceuticals visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: SUPN